Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.35 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18164944 | 0.89 | LPAR1 (0.32) | FABP3P2RY10GPR34SELP | |
| SCHEMBL18164946 | 0.88 | LPAR1 (0.36) | FABP3P2RY10GPR34PLA2G2A | |
| SCHEMBL18161730 | 0.87 | LPAR1 (0.50) | FABP3P2RY10GPR34 | |
| SCHEMBL18161723 | 0.87 | LPAR1 (0.50) | FABP3P2RY10GPR34 | |
| SCHEMBL18161721 | 0.83 | LPAR1 (0.41) | FABP3P2RY10GPR34PLA2G2AENPP2 | |
| SCHEMBL15043548 | 0.82 | FABP3 (0.45) | FABP3P2RY10GPR34PLA2G2AENPP2 | |
| SCHEMBL15161266 | 0.81 | PLA2G2C (0.46) | FABP3P2RY10GPR34PLA2G2AENPP2 | |
| SCHEMBL15161242 | 0.79 | FABP3 (0.55) | FABP3P2RY10GPR34 | |
| SCHEMBL18164942 | 0.78 | LPAR1 (0.38) | FABP3P2RY10GPR34 | |
| SCHEMBL18161727 | 0.78 | LPAR1 (0.53) | FABP3P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771385-B2 | Oxidized lipids | VASCULAR BIOGENICS LTD. (IL) | 2017-09-26 | — | — | US | disclosed |
| US-20160304544-A1 | Oxidized Lipids and Methods of Use Thereof | VASCULAR BIOGENICS LTD. (IL) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304544-A1 | Oxidized Lipids and Methods of Use Thereof | LPO, LIPA, GPX4 | FABP3 335/4885P2RY10 2636/4885GPR34 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.